Uso da ibogaína no tratamento da dependência química: uma revisão de literatura
DELOS Desarrollo Local Sostenible June 3, 2026 Ana Lara Mendonça, Déborah Rezende, Gabriela Alves et al.
Ibogaine, an indole alkaloid from Tabernanthe iboga, may reduce withdrawal symptoms, craving, and relapse in substance use disorders. A literature review of publications from PubMed, Scopus, Medline, Google Scholar, and SciELO shows ibogaine acts via multiple systems: glutamatergic, opioid, serotonergic, and nicotinic, with possible effects on neuroplasticity and reward circuits. Observational clinical studies indicate reductions in withdrawal and craving, and recent research describes improved psychiatric and cognitive outcomes in controlled settings. However, safety remains a major limitation, particularly the risk of corrected QT interval prolongation, ventricular arrhythmias, and serious cardiac events. The therapeutic potential is relevant but depends on randomized controlled trials, rigorous monitoring, clear regulatory criteria, and hospital protocols to reduce patient risks.